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Does Mineralocorticoid Receptor 
Antagonism Prevent Calcineurin 
inhibitor-induced nephrotoxicity?
Line Aas Mortensen1,2*, Claus Bistrup 1,2 and Helle Charlotte Thiesson1,2
1 Department of Nephrology, Odense University Hospital, Odense, Denmark, 2 Department of Clinical Research, University of 
Southern Denmark, Odense, Denmark
Calcineurin inhibitors have markedly reduced acute rejection rates in renal transplanta-
tion, thus significantly improved short-term outcome. The beneficial effects are, however, 
tampered by acute and chronic nephrotoxicity leading to interstitial fibrosis and tubular 
atrophy, which impairs long-term allograft survival. The mineralocorticoid hormone 
aldosterone induces fibrosis in numerous organs, including the kidney. Evidence from 
animal models suggests a beneficial effect of aldosterone antagonism in reducing cal-
cineurin inhibitor-induced nephrotoxicity. This review summarizes current evidence of 
mineralocorticoid receptor antagonism in animal models of calcineurin inhibitor-induced 
nephrotoxicity and the results from studies of mineralocorticoid antagonism in renal 
transplant patients.
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inTRODUCTiOn
The introduction of calcineurin inhibitors (CNIs) in renal transplantation has markedly reduced 
the occurrence of acute rejection and graft failure (1, 2). The immunosuppressive effect of CNI is, 
however, counterbalanced by adverse long term effects on kidney function leading to histological 
changes (i.e., arteriolar hyalinosis, striped interstitial fibrosis, tubular atrophy, and glomerulosclero-
sis) referred to as interstitial fibrosis and tubular atrophy (IF/TA) (3).
The mineralocorticoid hormone aldosterone stimulates fibrogenesis in multiple organs. Evidence 
from animal and human studies indicates that antagonizing aldosterone signaling via the mineralo-
corticoid receptor (MR) by MR antagonists reduces CNI nephrotoxicity.
This review summarizes current evidence from animal studies and outlines the potential benefits 
of MR antagonism in kidney transplant patients.
CALCineURin inHiBiTOR-inDUCeD nePHROTOXiCiTY
Although structurally different, both cyclosporine (CsA) and tacrolimus exert their effect by 
inhibiting the activity of calcineurin, a calcium- and calmodulin-dependent phosphatase involved 
in the activation of T-lymphocytes. Complexes of CsA/cyclophylin or tacrolimus/FKBP12 bind 
competitively to calcineurin, thereby preventing the dephosphorylation and subsequent activation 
Abbreviations: ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; BP, blood pressure; CNI, 
calcineurin inhibitor; CsA, cyclosporine A; CTGF, colony transforming growth factor; EGF, epithelial growth factor; GFR, 
glomerular filtration rate; H2O2, hydrogen peroxide; HSP-72, heat-shock protein 72; ICAM-1, intercellular adhesion molecule 
1; IF/TA, interstitial fibrosis and tubular atrophy; KIM-1, kidney injury molecule 1; MR, mineralocorticoid receptor; NADP, 
nicotinamide adenine dinucleotide phosphate; NFAT, nuclear factor of activated T-cells; Nfκβ, nuclear factor kappa B; PAI-1, 
plasminogen activator inhibitor 1; PDGF, platelet-derived growth factor; PRA, plasma renin activity; RAAS, renin-angiotensin-
aldosterone system; RBF, renal blood flow; RCT, randomized clinical trial; TGF-β, transforming growth factor β.
FiGURe 1 | Calcineurin inhibitors induce afferent arteriolar vasoconstriction through an effect on both mediators of endothelial dysfunction and a direct stimulatory 
effect on the RAAS-system. Vasoconstriction leads to reduced renal blood flow (acute CNI nephrotoxicity) and renal ischemia, which ultimately leads to inflammation 
and fibrosis (chronic CNI nephrotoxicity). The latter is further induced by a direct stimulatory effect on the major pro-fibrotic cytokine TGF-β. Simplified from Naesens 
et al. (3). CNI, calcineurin inhibitor; NO, nitric oxide; ET1, endothelin 1; RAAS, renin-angiotensin-aldosterone system; TGF-β, transforming growth factor β; ROS, 
reactive oxygen species; IF/TA, interstitial fibrosis and tubular atrophy.
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of nuclear factor of activated T-cells (NFAT). Activated NFAT 
promotes transcription of interleukin-2, which is pivotal for the 
activation of T-lymphocytes (4).
Nephrotoxicity has long been recognized as an adverse effect of 
CNI leading to chronic allograft failure and ultimately increased 
morbidity and mortality, mainly due to cardiovascular disease 
(5). Acute CNI nephrotoxicity is induced by vasoconstriction 
due to an imbalance between vasodilating and vasoconstricting 
factors and is reversible, whereas chronic CNI nephrotoxicity 
is considered to be irreversible. The proposed pathways of CNI 
nephrotoxicity are summarized in Figure  1. For an extensive 
review of CNI induced nephrotoxicity, see Ref. (3).
Attempts to prevent or reduce CNI nephrotoxicity in humans 
have focused on angiotensin antagonism or vasodilating agents. 
Although central in the hypothesized mechanism of CNI nephro-
toxicity, studies targeting the effects of angiotensin II have not 
yielded the expected results on long-term allograft survival. One 
randomized clinical trial (RCT), although designed to evaluate 
the effect of angiotensin converting enzyme inhibitor (ACEI) 
ramipril on cardiovascular outcomes in renal transplant patients, 
did not show any difference in long-term renal function when 
compared to placebo (6). Similarly, the angiotensin receptor 
blocker (ARB) losartan did not have an effect on the composite 
endpoint of interstitial volume expansion and end-stage renal 
disease in 153 renal transplant patients after 5  years (7). Early 
studies indicated a beneficial effect of calcium channel antagonists 
in both short- (8) and long-term renal allograft function (9, 10); 
however, results have been somewhat conflicting [summarized in 
Ref. (3)] and have not translated into clinical practice. Whether 
the beneficial effect of calcium antagonists on renal function is 
mainly due to pre-renal factors or due to reduced renal fibrosis 
remains to be investigated. Studies of nitric oxide (NO) donors or 
vasodilatory prostanoids in humans and animal studies of anti-
transforming growth factor β (TGF-β), antioxidants, statins, and 
magnesium have not shown a beneficial effect on kidney function 
(3). An alternative way to reduce CNI nephrotoxicity is via CNI 
minimization or complete CNI withdrawal; however, the major-
ity of attempts have resulted in higher acute rejection rates (11). 
Of interest are the belatacept-protocols, showing superior graft 
function with belatacept for 7–10  years when compared with 
CsA despite higher rates of early acute rejection in the belatacept 
groups (12, 13). Adverse event rates were similar (12). The use of 
belatacept as an alternative to CNI in solid organ transplantation 
has been summarized in a recent review (14).
The relative contribution of CNI nephrotoxicity to late allo-
graft failure has been the object of debate in recent years (15). 
Early reports indicated a prevalence of chronic CNI nephro-
toxicity of almost 100% in renal allograft biopsies after 10 years 
(16), which was supported by the finding of IF/TA in a large 
proportion of kidney biopsies from non-renal transplant patients 
(17). Since then, standard therapy has changed from high dose 
CsA toward lower-dose tacrolimus (18). Induction therapy in 
combination with mycophenolate has made CNI minimization 
possible. A recent study by Nankivell et al. compared sequential 
kidney graft biopsies from the CsA era (1988–1998) with the 
tacrolimus era (1999–2012). These showed a lower prevalence of 
chronic histological lesions in the tacrolimus group, indicating 
lower nephrotoxicity of current protocols. However, both cellular 
FiGURe 2 | Aldosterone induces vasoconstriction via MR in vascular smooth muscle cells and through reduced bioavailability of nitric oxide. Also, aldosterone 
stimulates the formation of ROS further worsened by vasoconstriction. Activation of pro-inflammatory transcription factors as well as the direct stimulation of 
cytokines and leukocyte adhesion to the vessel wall leads to inflammation, which contributes to tissue fibrosis. A, aldosterone; MR, mineralocorticoid receptor; MRA, 
MR antagonist; ROS, reactive oxygen species; TGF-β, transforming growth factor β; PAI-1, plasminogen activator inhibitor 1; ET-1, endothelin 1; CTFG, colony 
transforming growth factor; ICAM-1, intercellular adhesion molecule 1; NFκβ, nuclear factor κβ; AP-1, activator protein 1.
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and humoral acute rejection rates were significantly lower in the 
tacrolimus era (19) where mycophenolate had also replaced aza-
thioprine. Hence, the superior results of the tacrolimus era might 
be more complex than merely CNI minimization and reflect both 
immunological and non-immunological advances.
ALDOSTeROne AnD KiDneY FiBROSiS
Aldosterone regulates sodium and water balance via the MR in 
the kidney but is also involved in deleterious processes leading 
to fibrosis including vasoconstriction, inflammation, and oxida-
tive stress (Figure 2). Upon aldosterone binding to the MR, the 
receptor translocates to the nucleus where it regulates gene tran-
scription (20). To date, two steroidal MR antagonists have been 
approved for clinical use, namely spironolactone and eplerenone. 
Recommended dosages for both drugs are 25–50  mg daily in 
heart failure and up to 400 mg daily for spironolactone in hyper-
aldosteronism and liver cirrhosis with ascites. Spironolactone 
competitively binds to the MR with a high affinity, but also exerts 
antiandrogenic side effects through binding to the progesterone 
and androgen receptors (21). Eplerenone is more selective to the 
MR with fewer antiandrogenic side effects, but simultaneously has 
a lower affinity for the MR, hence is less potent (22). Much effort 
has gone into developing newer compounds with high affinity 
and high selectivity. The non-steroidal MR antagonist finerenone 
is currently undergoing phase III clinical trials in heart failure and 
diabetic kidney disease. Further, several other MR antagonists are 
in the pipeline (23).
Mineralocorticoid receptors are expressed in endothelial- and 
vascular smooth muscle cells, cardiomyocytes, mesangial cells, 
and podocytes in the kidney, adipocytes and a number of cir-
culating cells, e.g., monocytes, macrophages, and dendritic cells 
(24). Aldosterone induces vasoconstriction, particularly under 
conditions of endothelial damage, likely through a direct action 
on vascular smooth muscle cells (25), and further reduces bio-
availability of the potent vasodilator NO through MR-dependent 
mechanisms (26). This imbalance between vasoconstriction and 
vasodilation is commonly referred to as endothelial dysfunction 
and is associated with increased cardiovascular morbidity and 
mortality (25). MR antagonism has shown promising results in 
large scale RCTs in congestive heart failure (27, 28) reducing 
both morbidity and all-cause mortality. In addition to endothelial 
dysfunction, aldosterone stimulates the generation of reactive 
oxygen species by increasing the activity of nicotinamide adenine 
dinucleotide phosphate oxidase and by reducing the expres-
sion of glucose-6-phosphate dehydrogenase. This leads to the 
formation of superoxide and hydrogen peroxide, which in turn 
activate pro-inflammatory transcription factors nuclear factor 
kappa B (Nfκβ) and activator protein 1. Also, the aldosterone/
MR complex directly stimulates pro-inflammatory growth fac-
tors and cytokines [e.g., TGF-β, plasminogen activator inhibitor 
1 (PAI-1), endothelin 1, and colony transforming growth factor 
(CTGF)]. MR located in endothelial cells stimulates expression 
of the intercellular adhesion molecule 1, which facilitates the 
adhesion of leukocytes to the endothelium (24). The inflamma-
tory environment hereby created plays a major part in initiating 
fibrogenesis (29).
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Several clinical studies have evaluated the use of MR antago-
nists in chronic kidney disease. Results have been summarized in 
two systematic reviews including 27 and 19 studies, respectively, 
comprising 33 different trials. Most trials investigated the addi-
tion of MR antagonists to ACEI or ARB. Currie et al. reported a 
reduction of protein excretion of 38.7 ± 21.5% in any measure of 
protein/albumin excretion including all 19 trials associated with 
MR antagonism, which could be explained by a reduction of blood 
pressure (BP) (30). Bolignano et al. reported significantly reduced 
protein excretion rates for both spironolactone and eplerenone 
groups in addition to ACEI/ARB when compared to placebo (31). 
None of the included studies were powered to evaluate the effect 
on long term kidney function.
Cnis AnD THe Renin-AnGiOTenSin-
ALDOSTeROne SYSTeM (RAAS)
Cyclosporine A directly stimulates renin synthesis in the 
juxtaglomerular apparatus in rats and humans and further 
increases plasma renin activity (PRA) in rats, but this finding 
has not been reproduced in humans (32). On the contrary, early 
reports indicated that CsA reduced PRA and did not alter aldos-
terone levels in both healthy controls (33) and renal transplant 
patients (34). This difference between rats and humans could 
reflect physiological differences between species, but could also 
be related to differences in dosage and duration of treatment 
(32). A recent RCT measured PRA and plasma aldosterone at 
baseline and annually for 5 years in kidney transplant patients 
randomized to losartan or placebo. The majority of PRA and 
plasma aldosterone measurements in both groups were within 
normal range. Interestingly, higher aldosterone levels were asso-
ciated with inferior graft function (35). It has been hypothesized 
that intrarenal RAAS contributes to CNI nephrotoxicity (32). 
Eplerenone reduces fibrosis and renal mRNA expression of col-
lagen, TGF-β, and PAI-1 in adrenalectomized rats, indicating an 
influence of locally produced aldosterone (36). The importance 
of intrarenal activation of RAAS needs further investigation. As 
outlined in Figures 1 and 2, many deleterious processes related 
to aldosterone are represented in the chain of events leading to 
acute and chronic CNI nephrotoxicity explaining the rationale to 
investigate the effect of MR antagonism in CNI nephrotoxicity.
eFFeCTS OF MR AnTAGOniSM  
in AniMAL MODeLS OF Cni 
nePHROTOXiCiTY
Acute Cni nephrotoxicity
Acute CNI nephrotoxicity is characterized by vasoconstriction 
of the afferent arteriole leading to a decreased renal blood flow 
(RBF) and subsequently reduced glomerular filtration. Several 
groups have demonstrated an effect of MR antagonism prevent-
ing the reduction of RBF following CsA (Table 1). Perez-Rojas 
et al. demonstrated a reduction of RBF in CsA-treated rats. This 
effect was abolished by spironolactone, which also increased 
glomerular filtration rates (GFR) (37). The beneficial effect of 
spironolactone on kidney function in acute CNI nephrotoxicity 
5Mortensen et al. MR Antagonism Prevents CNI Nephrotoxicity
Frontiers in Medicine | www.frontiersin.org November 2017 | Volume 4 | Article 210
seen in chronic rejection in humans (49), thereby reflecting 
both immunologic and non-immunologic allograft damage. The 
observation that there was no fibrosis in kidneys from isografted 
animals despite CsA-treatment and extensive fibrosis in allo-
grafted animals highlights an immunological fibrogenesis rather 
than induced by CsA.
Blood Pressure
In contrast to CNI treatment in humans, rat models of CNI 
nephrotoxicity are not generally associated with hypertension. 
Accordingly, the majority of studies in chronic CNI nephrotoxic-
ity did not find any significant effect of neither CNI treatment nor 
MR antagonist on BP by invasive (48) or non-invasive measure-
ments (43, 47). One group, however, did find a significant increase 
in both daytime and nighttime BP in the CsA group compared 
to controls evaluated by intraarterial measurements in conscious 
animals. Eplerenone reduced BP during the resting period (45).
Proteinuria
Only one of the reported studies of chronic CNI nephrotoxicity 
showed reduced proteinuria during MR antagonism (36). One 
study even reported a tendency for a lower grade of proteinuria 
in the CsA group compared to vehicle and spironolactone groups 
(43). This observation could be partly explained by the simultane-
ous reduction of GFR but could also reflect differences between 
rats and humans.
Fibrosis
Feria et  al. found less tubulointerstitial fibrosis in the spirono-
lactone group (43). This was later confirmed by Macunluoglu 
et al. with all samples in the CsA-group displaying moderate to 
severe interstitial fibrosis (>25% affected area) compared to only 
one-fourth of samples in the spironolactone-group (44). Nielsen 
et al. showed increased volume fraction of renal interstitium in 
the CsA-group compared to controls, which was reduced in the 
eplerenone-group (45). Perez-Rojas et al. investigated the effect of 
MR antagonism initiated after established chronic CNI nephro-
toxicity. After 18  days of CsA treatment, kidney sections from 
six rats displayed 20.2% tubulointerstitial fibrosis. Interestingly, 
spironolactone, when initiated at day 18, seemed to slow the pro-
gression of fibrosis at day 36 compared to CsA alone (48). Feria 
et al. and Nielsen et al. further demonstrated less arteriolopathy in 
groups treated with MR antagonists compared with CsA (43, 45).
Markers of Kidney Damage
In addition to histological changes in chronic CNI nephrotoxicity, 
focus has been on identifying markers of fibrosis. The molecular 
regulation of the fibrotic processes is an intricate cascade of 
cytokines and growth factors leading to increased transcription 
of constituents of fibrosis, i.e., collagen I, III, and fibronectin. 
CsA increases several fibrogenic markers in models of chronic 
CNI nephrotoxicity. One of the major pro-fibrotic cytokines is 
TGF-β acting via (1) the canonical pathway to activate transcrip-
tion factors Smad2 and Smad3, which, in complex with Smad4, 
act to induce the transcription of pro-fibrotic molecules or (2) 
the non-canonical, Smad-independent pathways activating 
mitogen-activated protein kinases, c-Jun terminal kinase, p38, 
was already highlighted in the 1980s (38–40). Similar results have 
been achieved using eplerenone (41). Recent evidence points 
toward MR in vascular smooth muscle cells to play a role in the 
vasoconstriction associated with acute CNI nephrotoxicity (42). 
Regarding structural changes related to acute CNI nephrotoxic-
ity, Nielsen et  al. demonstrated a reduction of tubular hyaline 
vacuolization and arteriolar depositions by eplerenone (41). 
Also, McAuley et  al. found that spironolactone significantly 
decreased urinary tubular damage marker N-acetyl-beta-d-
glucosaminidase (38).
Chronic Cni nephrotoxicity
Several aspects of chronic CNI nephrotoxicity in rat models 
have been investigated. Most studies initiate MR antagonists in 
parallel with CsA treatment, thus investigating if chronic kidney 
damage can be prevented (36, 37, 43–47). One study, however, 
investigated whether MR antagonism was beneficial after devel-
opment of IF/TA. This showed improvement of GFR, fibrosis, 
and apoptosis, while all parameters further deteriorated in the 
non-MR antagonist group (=CsA-group) (48).
Renal Blood Flow
Similar to acute CNI nephrotoxicity, CsA has been shown to 
reduce RBF in rat models of chronic CNI nephrotoxicity, as 
indirectly indicated by constriction of glomeruli. This constric-
tion was partly reverted by spironolactone (48). The molecular 
background for the vasoconstriction was investigated in sodium-
depleted rats (37). They found an upregulation of prorenin by 
CsA, reverted by spironolactone. This study further demonstrated 
that the addition of spironolactone resulted in downregulation of 
the renal expression of endothelin A receptors and upregulation 
of endothelin B receptors, favoring vasodilation. Spironolactone 
had no influence on endothelin expression, adenosine pathways, 
and cyclooxygenase 2 mRNA levels (37). Taken together, this 
indicates that the beneficial effect of MR antagonism on renal 
vasoconstriction in chronic CNI nephrotoxicity involves both 
RAAS and endothelin pathways.
Glomerular Filtration Rate
The majority of studies on chronic CNI nephrotoxicity in rats 
demonstrate a beneficial effect of MR antagonism on GFR (37, 
43–45, 48). This relates to reduced renal vasoconstriction, but a 
likely contribution is the reduction of structural changes. One 
study failed to reach significance evaluating GFR based on 
s-creatinine levels after 5  weeks of spironolactone (46). In this 
study, blood concentrations of CsA were substantially lower than 
in similar studies and all kidneys were morphologically normal.
To our knowledge, only one study has investigated the effect 
of MR antagonsim in a model of renal transplantation in rats 
(47). In this study, 16 rats had kidney grafts from the same strain 
(Dark agouti—isografted) and 14 rats had kidney grafts from a 
different strain (Dark Agouti to Wistar Furth—allografted). All 
animals received CsA and were randomized to spironolactone 
20 mg/kg/day or vehicle. After 12 weeks, there was no difference 
in GFR between vehicle and spironolactone groups in both iso- 
and allografted animals as evaluated by creatinine clearance. The 
allograft model was developed to mimic the histologic changes 
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and extracellular-signal regulated kinase to increase the tran-
scription of other pro-fibrotic cytokines as well as collagens and 
fibronectin (50, 51). Several studies have demonstrated increased 
renal mRNA levels of TGF-β in response to CsA, an increase that 
was attenuated by MR antagonsim (36, 43, 48). Macunluoglu 
et al. demonstrated a similar effect of MR antagonists by immu-
nostaining of renal tissue (44).
In accordance with findings regarding TGF-β, CsA increased 
renal mRNA levels of both collagen I (36, 43) and fibronectin 
(43). This increase was mitigated by MR antagonism. CsA also 
increased α-smooth muscle actin—a marker of activated fibro-
blasts, although these levels were independent of MR antagonism 
(45), and the renal mRNA levels of several other profibrotic 
cytokines, i.e., platelet-derived growth factor (PDGF) (44), CTGF, 
and PAI-1 (36) all of which participate in the profibrotic cascade 
involving TGF-β. Concomitant MR antagonism significantly 
reduced levels of PDGF (44), and PAI-1, but not CTGF (36).
Tubular atrophy associated with renal fibrosis is partly due 
to apoptosis of tubular epithelial cells. Perez-Rojas et al. found a 
significant reduction of apoptotic nuclei in renal cortex by addi-
tion of spironolactone to CsA. This was paralleled by a reduction 
of apoptosis-marker procaspase 3 in the spironolactone group. 
Also, they demonstrated an increase in both cortical and urinary 
mRNA levels of kidney injury molecule 1 (KIM-1) in response to 
CsA and subsequent reduction by spironolactone (48).
Epithelial growth factor (EGF) stimulates regeneration of 
the tubular epithelium after ischemic damage and Feria et  al. 
found a significant reduction of cortical EGF caused by CsA. 
Spironolactone diminished this reduction when added to CsA, but 
interestingly when administered alone also significantly reduced 
cortical EGF levels compared with vehicle (43). Nielsen et  al. 
demonstrated a reduction of the epithelial marker E-Cadherin in 
response to CsA, which was attenuated by eplerenone (45). Taken 
together, this indicates a protective effect of MR antagonists on 
tubular epithelial cells. Whether this is mainly due to preven-
tion of TGF-β-induced apoptosis and the reduction of ischemic 
damage to the kidney as a result of higher RBF remains to be 
established. None of the identified animal studies have addressed 
the potential effect of MR antagonism in reducing inflammation 
and endothelial dysfunction. These pathways may contribute to 
the renoprotection conferred by MR antagonists. For an overview 
of the included studies, see Table 1.
eFFeCTS OF MR AnTAGOniSTS in 
RenAL TRAnSPLAnT PATienTS
Despite evidence from animal studies, very few studies have 
investigated the effect of MR antagonists preventing CNI 
nephrotoxicity in humans. This is partly due to concerns regard-
ing hyperkalemia related to MR antagonism in patients with 
impaired renal function and concomitant CNI treatment. This 
issue was addressed in a recent publication testing the safety 
of eplerenone 25  mg/day for 8  weeks in a group of 31 kidney 
transplant patients treated with CsA. Median eGFR was 41 mL/
min. A slight increase in serum-potassium was detected already 
after 2 days of treatment. Nine patients had at least one episode 
of mild hyperkalemia (>5.0 mmol/L) but only one patient experi-
enced moderate hyperkalemia (>5.5 mmol/L). No patients were 
withdrawn from the study due to hyperkalemia. There was no 
change in systolic BP, body weight, or s-bicarbonate after 8 weeks 
of treatment (52).
One single-blind RCT has investigated the effect of MR antag-
onism in a pediatric kidney transplant population. Twenty-four 
children with chronic allograft nephropathy were randomized to 
eplerenone or placebo for 24 months. Although underpowered 
to provide definite evidence, there was a tendency toward lower 
levels of tubulointerstitial fibrosis in the eplerenone group after 
24 months (p = 0.06), but no significant changes in albuminuria, 
BP and eGFR. No difference was detected in urinary KIM-1, 
heat-shock protein 72 (HSP-72), 8-hydroxy-2-deoxyguanosine 
(marker of oxidative stress), or serum TGF-β (53).
The effect of MR antagonism on proteinuria has been addressed 
in an open label study of 11 proteinuric kidney transplant patients, 
who already received both ACEI and ARB. This study found a 
significant reduction in protein excretion from 4.4 to 2.7 g/day 
after the first month of treatment with spironolactone 25 mg/day, 
an effect that was sustained for the full 6 months of intervention. 
There was no difference in BP or GFR during this period (54).
The proposed effect of MR antagonists to reduce renal 
ischemia and thereby oxidative stress was investigated in a 
double-blind RCT including 20 kidney transplant recipients 
randomized to spironolactone 25 mg or placebo on the day before 
transplantation and 3 days after. The aim was to investigate the 
effect of MR antagonism on oxidative stress relating to ischemia/
reperfusion injury. Urinary hydrogen peroxide (H2O2) levels were 
significantly lower in the spironolactone group on the fifth post-
operative day. There was no difference in tubular damage markers 
KIM-1, interleukin 18, or HSP-72. However, three patients in 
the spironolactone group displayed delayed graft function and 
subsequent biopsies revealed acute rejection in two of these. In 
the placebo group, one patient had rejection. It is worth noticing 
that B-Tac trough levels were possibly lower in the spironolactone 
group (3.65 vs. 6.05 ng/mL), although this was not significant. A 
difference in B-tacrolimus concentration could account for the 
greater rejection rate in the spironolactone group, but could also 
contribute to lower H2O2 levels, since tacrolimus reduces RBF, 
thereby inducing oxidative stress (55). The included human stud-
ies are summarized in Table 2.
CURRenT AnD FUTURe TRiALS
Evidence underlines the need for sufficiently powered RCTs to 
evaluate the effect of MR antagonism in the kidney transplant 
population. Three ongoing trials were identified (https://
ClinicalTrials.gov): (I) RCT (NCT02490904) investigating the 
effect of eplerenone for four days in relation to kidney transplan-
tation in 132 patients on short- and long-term kidney function; 
(II) open label study (NCT01510795) evaluating the chronic 
BANFF-scores in 40 patients after 6  months of spironolactone 
as compared with a retrospective control group, and (III) RCT 
investigating the effect of spironolactone for 3  years in 170 
patients with regards to preserving kidney function and reducing 
renal fibrosis (NCT01602861).
TABLe 2 | Included studies in renal transplant patients.
Reference number 
of 
subjects
intervention Design Result
Bertocchio 
et al. (52)
31 EPL 25 mg/day 
for 8 weeks
Prospective, 
open-label
No significant 
hyperkalemia
Medeiros 
et al. (53)
24 EPL 25 mg/day 
for 24 months
Prospective, 
randomized, 
single-blind, 
placebo 
controlled
Stable kidney 
function
Tendency toward 
lower proteinuria 
and less fibrosis 
(NS)
Gonzalez 
Monte  
et al. (54)
11 Spiro 25 mg/day 
for 6 months
Prospective, 
open-label
Significant 
reduction of 
proteinuria
Ojeda-
Cervantes 
et al. (55)
20 Spiro 25 mg/
day 24 h prior 
to kidney 
transplantation 
and 3 days after
Randomized, 
double blind, 
placebo 
controlled
Reduced urinary 
H2O2
No difference in 
tubular damage 
markers
EPL, eplerenone; Spiro, spironolactone; NS, not significant; H2O2, hydrogen 
peroxide.
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COnCLUSiOn AnD PeRSPeCTiveS
Calcineurin inhibitor causes renal fibrosis likely due to altered 
hemodynamics and a direct stimulatory effect on fibrogenic 
factors. Rat models of acute and chronic CNI nephrotoxicity 
have shown beneficial effects of MR antagonism in preserving 
GFR and reducing fibrosis. This is likely due to an increased RBF 
attenuating ischemic damage to the kidneys, in combination with 
a direct inhibitory action on pro-fibrotic cytokines. Few human 
studies have addressed this hypothesis. Improving long-term 
allograft survival remains a key challenge in renal transplantation 
with the potential to improve quality of life, morbidity, and mor-
tality of the affected individuals. Results of future and ongoing 
clinical trials may clarify if aldosterone antagonism can prevent 
or improve CNI nephrotoxicity in humans.
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